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Abstract
Background: The Helicase-Like Transcription Factor (HLTF/SMARCA3) belongs to the family of
SWI/SNF proteins that use the energy of ATP hydrolysis to remodel chromatin in a variety of
cellular processes. Several SWI/SNF genes are disrupted in cancer, suggesting a role of tumor
suppressor. Similarly, the HLTF gene was recently found to be inactivated by hypermethylation in
a number of advanced colon and gastric tumors. However, other evidences indicated a 20-fold
HLTF overexpression in cell lines derived from various neoplasms (ovary, breast, cervix, kidney...).
Results: In the present study, we investigated HLTF expression by immunohistochemistry in a
model of kidney tumors induced by continuous administration of diethylstilbestrol to male Syrian
golden hamsters. A strong labeling was already detected in small tumor buds, making HLTF an early
cancer marker in this model. Although every cell stained for HLTF at this early stage, the number
of HLTF-positive cells decreased to 10% with cancer progression, and these positive cells were
dispersed in the tumor mass. HLTF expression was conserved in the HKT-1097 cell line established
from kidney tumors, but again only 10% of positive cells were found in xenografts produced by
HKT-1097 cells in nude mice.
Conclusion: In conclusion, our data suggest that HLTF gene activation is linked to initial steps of
carcinogenesis in this model and should be investigated in early stages of other neoplasms.
Background
The human helicase-like transcription factor (HLTF;
SMARCA3 in OMIM) presents a RING-finger motif as well
as the 7 DNA helicase domains characterizing the SWI/
SNF family of chromatin remodeling factors [1]. Albeit
devoid of helicase activity on naked DNA, these proteins
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are DNA-dependent ATPases that modify chromatin
structure. SWI/SNF proteins displace nucleosomes on
DNA by the propagation of a DNA bulge, i.e. a local dis-
tortion of the DNA double helix wrapped around the his-
tone core (reviewed by [2]). SWI/SNF proteins were
initially identified in yeast by the fact that their inactiva-
tion caused a global alteration of gene transcription. Some
SWI/SNF proteins have been implicated in cellular func-
tions so diverse as chromosome segregation (lodestar; [3]),
nucleotide excision repair (RAD4, ERCC6, and RAD16;
e.g. [4]), nucleosome reassembly after replication (I-SWI;
[5]) and DNA double-strand break repair [6]. However,
they have been mostly studied for their involvement in
the regulation of transcription, where they act as large
multiunit complexes (such as RSC, NURF, CHRAC,
NURD...; reviewed in [7]).
Most members of the SWI/SNF protein family lack a
sequence-specific DNA binding domain and are thought
to access promoters by interactions with DNA-bound
trans elements. In contrast, HLTF can be directly targeted
to specific promoters thanks to a specific DNA binding
domain. On the basis of this structural feature, HLTF was
independently described under different names by several
groups that used different target genes, such as the HIV
proximal promoter and SV40 enhancers (HIP116; [8]),
the human or rat plasminogen activator inhibitor 1 (PAI-
1) promoter (HLTF; [1]; P113; [9]), the rabbit uteroglobin
promoter (RUSH; [10]), the myosin light chain gene
enhancer (Zbu1; [11]), and a cis element in the β-globin
locus control region (HLTF; [12]). Yet, direct evidences for
a role of HLTF in transcription have only been found in
the PAI-1 gene [1,9,12] and in the β-globin LCR [12]. Two
HLTF protein variants were identified. They differed by
alternative translation initiation in the same open reading
frame (HLTFMet1 and HLTFMet123): transcriptional
activity was only shown for the short variant [1,13].
There are indications that HLTF acts as a modulator of cell
differentiation during embryogenesis and adult life. In the
mouse embryo, HLTF/Zbu1 mRNA and protein were first
detected in heart, skeletal muscle and brain at late stages
of development (18.5 days pc). Thereafter HLTF expres-
sion extended to all postnatal tissues, in parallel with ter-
minal differentiation [11]. The concept that HLTF might
participate in the regulation of differentiation is also sup-
ported by the time course of its expression during erythro-
cyte differentiation, and the fact that forced HLTF
overexpression results in inappropriate β-globin gene
switching in a human leukemia cell line [12].
Many studies have also implicated SWI/SNF genes in can-
cer (reviewed by [14]. Human tumors of various origins
presented inactivating mutations affecting hSNF5[15],
SMARCB1/INI1[16], RAD54b [17], BRG1 or hBRM associ-
ated factors [18] genes. The HLTF RING domain is highly
similar to the RING domain of BRCA1, a tumor suppres-
sor gene mutated in breast and ovarian cancer. Similarly,
the HLTF gene was methylated and epigenetically silenced
in 30–70% of human colon and gastric cancers, suggest-
ing a role in tumor suppression [19,20]. In contrast, a 20-
fold increase in mouse HLTF/Zbu1 mRNA concentration
has been observed in several established cell lines of
tumor origin (HeLa, MCF7, ...,[11]) suggesting that HLTF
over-expression could be associated with neoplastic trans-
formation. However, this does not necessarily indicate
that HLTF play a direct role in malignant cell transforma-
tion since these cell lines were already transformed.
These conflicting data prompted us to investigate HLTF
during malignant transformation and tumor progression.
Since the original observation of Kirkman and Bacon [21]
that treatment with diethylstilbestrol (DES) provokes the
appearance of kidney tumors in male Syrian hamsters,
renal neoplasms induced by the continuous administra-
tion of natural (i.e. 17β-estradiol) or synthetic (i.e. DES)
estrogens to these animals have been extensively utilized
in studies pertaining to hormonal and renal carcinogene-
sis (see reviews in [22,23]). The major advantage of this
model lies in the reproducible time-course of tumorigen-
esis. In DES-treated hamsters, microscopically distin-
guishable kidney tumors start appearing 6 months after
the beginning of drug exposure [24,25]. Tumor formation
is preceded by cytological abnormalities and tissue injury
which reflect early steps in the chain of events leading to
tumorigenesis [24,26-28]. In particular, examination of
renal tissue sections from animals exposed to DES for 4–
6 months reveals the presence of focal histological abnor-
malities which may be considered as early signs of neo-
plastic transformation. Interestingly, these tumorous
buds, as well as well-developed kidney malignancies
exhibit a variety of lineage markers pointing to a mesen-
chymal origin (vimentin) and suggesting a relationship
with cells of the neuroectodermal lineage (e.g. S100 pro-
tein, GFAP). This intriguing finding has led some of us to
postulate that DES-induced kidney tumors actually derive
from Schwann cells or peripheral nerve sheath cells,
although other histological origins cannot be dismissed
[25].
A few years ago, primary cultures of kidney tumor samples
from hamsters exposed to DES for 11 months resulted in
cell immortalization and the emergence of a new estab-
lished cell line (HKT-1097). HKT-1097 cells express most
markers characterizing renal tumors in vivo [29,30] and
exhibit carcinogenic properties in nude mice (F. Journé,
unpublished data).
In the present study, two rabbit antisera raised against
individual HLTF protein variants were used for immuno-Molecular Cancer 2006, 5:23 http://www.molecular-cancer.com/content/5/1/23
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cytochemical analyses of DES-induced kidney tumors at
various stages of development, and demonstrated HLTF
over-expression as an early event. Moreover, this high
expression level was maintained in the tumor-derived
HKT-1097 cell line.
Methods
Cell culture
The major characteristics of the HKT-1097 cell line
(ECAAC n° 98061003, DSMZ n° AAC 445) were
described in previous publications [29,30]. Cell cultures
were maintained at 37°C in a cell incubator with humid
atmosphere at 5% CO2. Cells were propagated in T75-
flasks (Orange Scientific, Braine-l'Alleud, Belgium) con-
taining Dulbecco's Modified Essential Medium (DMEM,
BioWhittaker Europe, Verviers, Belgium) supplemented
with Phenol Red, 10 % fetal bovine serum (FBS, HyClone,
Logan, Utah), 25 mM N-2-hydroxyethylpiperazine-N'-2-
ethanesulfonic acid (HEPES), 2 mM L-glutamine, 100 U/
ml penicillin G, 100 μg/ml streptomycin, and 0.25 μg/ml
amphotericin B (DMEM-FBS) (supplements from BioW-
hittaker or Gibco-Invitrogen, Merelbeke, Belgium). Cell
cultures were passed once a week (split ratio 1:300) and
were fed fresh medium every 2–3 days. For routine subcul-
ture and cell plating in preparation of immunofluores-
cence studies, cells were dislodged from the vessel bottom
by treatment with trypsin-EDTA solution, suspended in
culture medium by vigorous pipetting and counted in a
model Z1 Coulter counter.
HKT-1097 tumor xenograph
HKT-1097 cells were plated at an initial density of 104
cells/cm2  in 75-cm2  flasks, grown for three days as
described above and harvested by trypsinization. After
centrifugation the cells were resuspended in serum-free
DMEM without Phenol Red, and their concentration
adjusted to 5 × 107 cells/ml. 200 μl aliquots of the cell sus-
pension were injected subcutaneously into the left flank
of male nude mice weighing 20–25 g (6 week old) (Swiss
strain; Iffa Credo, Brussels, Belgium). Development of the
tumor xenograft was monitored weekly. Mice were killed
by cervical dislocation and the tumors harvested at
necropsy, fixed in Duboscq-Brazil fluid and processed as
described above for immunohistochemistry. These exper-
iments had been performed at the Bordet animal facility
(accreditation n°LA 1230352) and approved by the Ethics
Committee for Animal Welfare of the "Université Libre de
Bruxelles".
Animals and treatment
Male Syrian hamsters (Mesocricetus auratus) weighing 70–
80 g (3–4 month old) were used throughout the study.
The animals were bred and maintained at the UMH ani-
mal facility accredited (n°LA 1500021) by the Belgian
Ministry of Middle Class and Agriculture, and the experi-
ments performed in compliance with the guidelines
edicted by authorities. Five groups of at least 4 animals
received chronic treatment with DES following a protocol
detailed previously [31,32]. Implants filled with 25 mg of
DES (Sigma; St Louis, MO) were inserted in the subcutane-
ous tissue of the shoulder area of anesthetized animals
and renewed every 2.5 months to maintain a constant
blood level of DES (approx. 13 ng/ml). Hamsters (at least
4 animals per time point) were terminated 1, 2, 4, 5, 6, 7,
9, 10 and 11 months after the first implantation. A group
of sham-operated animals (n = 4) and a group of
untreated animals (n = 4) of various ages (7–9 months)
were included as controls.
Antisera
Two putative immunogenic peptides corresponding to the
individual HLTF variants (see Result section) were defined
by accessibility prediction programs (Garnier software
from the EMBOSS software package; [33]), synthesized at
Eurogentec (Seraing, Belgium) and conjugated to a carrier
protein (keyhole limpet hemocyanin). Two rabbits were
challenged by three intradermal injections of each conju-
gate at two-week intervals, followed by a booster inocula-
tion one month later. The animals were bled 10 days after
the last immunization. The rabbits were housed in the
IBMM (Gosselies, Belgium) animal facility according to
standard protocols and in agreement with the Animal
Care and Use Committee of the "Université Libre de Brux-
elles" (n°LA 1500474).
Transcription/translation assays
In vitro transcription/translation assays were carried out in
a TNT rabbit reticulocyte lysate (Promega Corporation,
Madison, WI, USA) in the presence of T7 RNA polymerase
and [35S] cysteine (1,000 Ci/mM;Amersham Biosciences,
Roosendaal, The Netherlands). The cDNA template used
(pGEM-4Z-HLTF) has been previously described and
encodes both HLTF variants (Ding et al., 1996). A luci-
ferase cDNA template was substituted for the HLTF cDNA
as a control. The reaction mixtures were boiled in sample
buffer (2% SDS, 62.5 mM Tris-HCl pH 6.8, 5% β-mercap-
toethanol, 20% glycerol, 0.5% bromophenol blue, 18
mM DTE) and resolved by electrophoresis on 4–12%
polyacrylamide gels (SDS-PAGE). The gels were treated
with Amplify (Amersham Biosciences), and dried for
fluorography on a Kodak BioMax MR film (Amersham
Biosciences).
Immunoprecipitations
For immunoprecipitations, 15 μl [35S]-labelled  in vitro
transcription/translation products were incubated 2 hours
at 4°C with 10 μl rabbit antiserum in a 1 ml final volume
of 150 mM NaCl, 10 mM Tris, 1 mM EDTA, 0.5 mM
EGTA, 1% Triton X-100, 0.5 mM orthovanadate, 0.5 mM
PMSF and protease inhibitor cocktail (Roche DiagnosticsMolecular Cancer 2006, 5:23 http://www.molecular-cancer.com/content/5/1/23
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Belgium, Vilvoorde, Belgium). This was followed by a fur-
ther one-hour incubation with protein A-Sepharose (128
mg/ml; Amersham Biosciences). After centrifugation, the
pellets were washed 3 times in the immunoprecipitation
buffer, and suspended in sample buffer for analysis by
SDS-PAGE (4–12% gradient) followed by fluorography as
stated above.
Hamster HLTF cDNA sequences
PolyA(+) RNA was extracted with the Micro-FastTrack
mRNA isolation kit (Invitrogen) from 5 × 106 HKT-1097
cells. Reverse transcription was performed with random
primers and the MMLV reverse transcriptase (Promega)
according to the protocol provided by the manufacturer.
The primers used for PCR were 5' TTGCAGACTGTCCAG-
TATGG 3' (forward) and 5' ACTGGCATACTATAGCTTGG
3' (reverse); amplification was done with Pfu  DNA
polymerase (Promega) in a Mastercycler gradient (Eppen-
dorf) set for 35 cycles (40 sec at 95°C, 40 sec at 50 °C, 55
sec at 74°C). Protruding A's were added to the PCR prod-
uct with Taq DNA polymerase 15 min at 72°C and it was
ligated into the pCR4-TOPO vector (Invitrogen). Plasmid
DNA was extracted from transformed E. coli colonies with
the Wizard Plus SV Minipreps DNA Purification System
(Promega). Sequences were determined by the dideoxy-
nucleotide chain termination method with CEQ DTCS
Quick Start Kit and the CEQ2000 sequencer (Beckman-
Coulter). Sequences were analyzed on the Belgian EMBL
node http://www.be.embnet.org/ with the EMBOSS soft-
ware package.
Rapid amplification of cDNA 5' end was performed on
250 ng polyA(+) RNA with the FirstChoice RLM-RACE kit
(Ambion) according to the manufacturer's protocols. The
specific HLTF primers used were the following: 5' GCGT-
TCAGTTGTCATCTG 3' (outer), 5' ACTGGCATACTAT-
AGCTTGG 3' (inner). The products were resolved by
electrophoresis on a 1% agarose gel, the larger fragment
was extracted from the gel with the Qiaquick Gel extrac-
tion kit (Qiagen), cloned and sequenced as detailed
above.
Hamster genomic sequences
Genomic DNA was extracted from hamster liver with the
Scil DNA Tissue Kit in the KingFisher (ThermoLabs Sys-
tem) apparatus. 700 ng DNA were amplified by Pfu DNA
polymerase with primers mapping to exon 2: 5' TTGCA-
GACTGTCCAGTATGG 3' (forward) and 5' CCCGTG-
TAATAGCGTAGTCC 3' (reverse). A denaturation step of 3
min at 95°C was followed by 35 PCR cycles of 30 sec at
94°C, 60 sec at 56°C, 60 sec at 72°C. The resulting 166-
bp fragment was cloned and sequenced as detailed above.
Semiquantitative assessment of DES-induced renal tumors
Neoplasms in hamster kidneys were analyzed as described
previously [25] and graded according to size and gross
morphology. Briefly, three stages were defined on the
basis of the following criteria: 1) Tumorous buds: well-
defined, small clusters of tumor cells surrounded by nor-
mal kidney tissue (5–200 cells); 2) Medium-sized tumors:
more important clusters of tumor cells infiltrating normal
kidney tissue (approx. diameter of 150 – 600 μm); 3)
Large invasive tumors of large diameter extensively infil-
trating the kidney (>300.000 μm2 and up to 80 mm2).
These stages are illustrated in Figures 3 and 4.
Reagents
All reagents for immunohistochemistry (primary antibod-
ies, conjugated antibodies or F(ab)2 fragments, ABC kit)
came from Dakopatts (Glostrup, Denmark) except when
stated otherwise.
Tissue immunohistochemistry
Immediately after sacrifice, kidney samples were fixed by
immersion in alcoholic Bouin mixture (Duboscq-Brazil
fluid) for 48 h and embedded in paraffin according to
standard procedures. Sections of 4–5 μm thickness were
cut serially with a Reichert Autocut 2040 microtome and
mounted on silane-coated glass slides.
Tissue sections were immunostained following a slightly
modified version of the streptavidin-biotin immunoper-
oxidase method (ABC method). The primary antibodies,
anti-HLTFMet1 (ART2) and anti-HLTFMet123 (ASE2),
were tested in preliminary studies to determine the opti-
mal dilutions, 1/350 and 1/300 respectively. The sensitiv-
ity of the method was increased by microwave pre-
treatment of dewaxed sections in 0.01 M citrate buffer
(pH 6.0) for 2 × 5 min at a power of 900 W. After micro-
wave treatment, the sections were incubated in 0.4%
hydrogen peroxide for 5 min and rinsed in PBS. Thereaf-
ter, the sections were successively exposed to avidin (0.1
mg/ml in PBS) and to biotin (0.1 mg/ml in PBS) for 20
min to block the reactivity for endogenous biotin. After
rinsing in PBS, the sections were preincubated in 5% nor-
mal goat serum in PBS (NGS-PBS) for 20 min and incu-
bated sequentially at room temperature in the following
solutions: (1) primary antiserum for 1 hour; (2) bioti-
nylated goat anti-rabbit IgG (diluted 1:50) for 20 min,
and (3) ABC complexes for 20 min. Bound peroxidase
activity was visualized by incubation with 0.02% 3, 3'-
diaminobenzidine – 0.01% H2O2 in PBS. The sections
were finally counterstained with PAS, hemalun and luxol
fast blue and mounted in a permanent medium. Study of
the distribution S100 protein relative to HLTF was per-
formed on consecutive sections using rabbit polyclonal
anti-S100 as a primary antibody and the demonstration
method described above.Molecular Cancer 2006, 5:23 http://www.molecular-cancer.com/content/5/1/23
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Immunofluorescence staining of cultured cells
For cell immunostaining, twelve-well plates containing
sterile round glass coverslips (15-mm diameter) were
seeded at a density of 5 × 103 cells/mm2. After 3 days of
growth, cell cultures were rinsed with Dulbecco's phos-
phate buffered saline (DPBS) and fixed at 4°C in 4% para-
formaldehyde in DPBS. After 15 min. the fixative was
replaced by DPBS where cells were kept at 4°C until
immunostaining. For the simultaneous demonstration of
vimentin and HLTF, the cells were incubated with a mix-
ture of mouse monoclonal anti-porcine vimentin and rab-
bit polyclonal anti-HLTF antibodies (ASE2 or ART2). This
was followed by exposure to a mixture of fluorescein iso-
thiocyanate (FITC)-conjugated goat anti-mouse immu-
noglobulins antibodies (F(ab)2 fragments) and
biotinylated swine anti-rabbit immunoglobulins antibod-
ies. HLTF-containing immunocomplexes were finally
demonstrated by incubating cell preparations with Texas
Red-conjugated streptavidin (Pierce, Rockford, ILL, USA).
For the simultaneous demonstration of lamin and HLTF,
cell preparations were first exposed to anti-HLTF antibod-
ies (ASE2 or ART2), followed by FITC-conjugated swine
anti-rabbit immunoglobulins antibodies (Vector Labora-
tories, Burlingame, CA). The next step consisted in an
incubation in presence of rabbit immunoglobulins in
order to saturate free binding sites of anti-rabbit immu-
noglobulins antibodies. Thereafter, cells were exposed to
goat polyclonal anti-lamin B antibodies (Santa Cruz Bio-
technology, Santa Cruz, CA), followed by biotinylated
rabbit anti-goat immunoglobulins antibodies. Finally,
lamin-containing immunocomplexes were demonstrated
by using Texas-Red-conjugated streptavidin as described
above. The preparations were mounted in Vectashield
mounting medium (Vector Laboratories, Inc., Burlin-
game, CA). Immunostained sections were examined on a
Leitz Orthoplan fluorescence microscope (Ploem system)
and the positive fields recorded with a digital camera
(Leica DC 300F).
Controls for the specificity of immunolabeling included
the omission of the primary antibody or the substitution
of non-immune sera for the primary antibodies. The spe-
cificity of anti-HLTF immunostainings was also checked
with primary antibodies previously incubated with the
corresponding synthetic peptide used as antigen. In each
case these controls were negative.
Results
Characterization of the antisera
Two human HLTF variants are expressed from the same
open reading frame and only differ by the translation start
site (Met1 or Met123) [1]. In order to raise an antiserum
(ART2) specific for the HLTFMet1 variant, we chose a
putative immunogenic peptide i.e. residues 42–56 (VIPP-
DDFLTSDEEVD) in the amino-terminal sequence missing
in the shorter variant. The HLTFMet123 sequence being
entirely included in the longer variant, we reasoned that
its amino-terminal region might differ in terms of confor-
mation from the corresponding sequence in HLTFMet1.
Indeed structure predictions indicated that a set of four
putative alpha helices were disrupted by the NH2-trunca-
tion in the shorter variant. Aiming to prepare an antise-
rum (ASE2) specific for HLTFMet123, we thus selected a
putative immunogenic peptide corresponding to residues
152 to 166 (GKEENRKAVSDQLKK), surmising that it
might be accessible in the short variant but hidden into
the HLTFMet1 conformation, at least in non-denaturing
conditions. In addition the above mentioned peptides
belong to the HLTF DNA binding domain that is highly
conserved in the available mammalian sequences (Gen-
Bank accession numbers: mouse:#AF165911, rabbit:
#U66564 and human: #AJ418064).
The specificity of these antisera was checked by immuno-
precipitation of the human HLTF variants expressed by
transcription/translation in a rabbit reticulocyte lysate in
the presence of [35S] cysteine. The HLTF cDNA template
(pGEM-4Z-HLTF;[1]) drove synthesis of the two protein
variants with apparent molecular weights of 110
(HLTFMet123) and 130 kDa (HLTFMet1) on SDS-PAGE,
together with incomplete translation products (Figure 1,
lanes 2 and 4). As expected, the ART2 antiserum reacted
specifically with HLTFMet1 (lane 3). The ASE2 antiserum
immunoprecipitated HLTFMet123 together with a small
amount of the larger variant (lane 1): this was not consid-
ered sufficient to affect serum specificity in subsequent
experiments. Neither antiserum reacted with the negative
control, i.e. in vitro translated luciferase (lanes 5–8).
Sequence of HLTF in the hamster
We wanted to check whether the human peptides used to
raise the antisera described above were conserved in the
hamster HLTF sequence. We surmised that the 5' part of
the HLTF cDNA encoding the DNA binding domain was
also well conserved in the hamster, and designed primers
for reverse transcription and amplification by PCR in this
region based on an alignment of the mouse, rabbit and
human cDNA sequences with the Matcher software [34]
from the EMBOSS software package. RT-PCR was per-
formed on polyA(+) RNA extracted from HKT-1097 cells,
the product was cloned into the pCR4  vector, and its
sequence was determined. Surprisingly, a 100% identity
with human HLTF was found over the 550 bp fragment,
suggesting a sample contamination. The experiment was
repeated on RNA extracted from hamster liver or testis,
confirming the sequence. Two other approaches were
used to demonstrate that no human cDNA contamination
had occurred. We first determined the sequence of a
genomic fragment amplified by PCR within exon 2 and it
was again 100% identical to human, confirming theMolecular Cancer 2006, 5:23 http://www.molecular-cancer.com/content/5/1/23
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deduced peptide sequence; a similar experiment could not
be performed for exon 4 because of its short size. We then
cloned cDNA's extending upstream from the second pep-
tide coding region by a 5' RACE approach: products ana-
lyzed were found to have 100% identity to the human
cDNA excepted for a 22-bp segment that was clearly differ-
ent (Figure 2). In conclusion, both antisera developed
against peptides of human HLTF could be used in the
hamster cancer model.
In vitro transcription/translation was performed in the presence of [35S] cysteine in a TNT rabbit reticulocyte lysate pro- grammed with either pGEM-4Z-HLTF encoding both HLTFMet1 and Met123 variants (lanes 1–4) or Luciferase T7 control plas- mid (lanes 5–8) Figure 1
In vitro transcription/translation was performed in the presence of [35S] cysteine in a TNT rabbit reticulocyte lysate pro-
grammed with either pGEM-4Z-HLTF encoding both HLTFMet1 and Met123 variants (lanes 1–4) or Luciferase T7 control plas-
mid (lanes 5–8). The products were resolved by electrophoresis on a 4–12% SDS-PAGE gradient and detected by 
autoradiography. The samples were either 1,5 μl of total in vitro translation products (lanes 2, 4, 6, and 8), or 15 μl of in vitro 
translation products immunoprecipitated with either the ASE2 antiserum directed against HLTFMet123 (lanes 1 and 5) or the 
ART2 antiserum directed against HLTFMet1 (lanes 3 and 7). The autoradiography was exposed 3 days. The sizes of the molec-
ular weight markers (MW) are given in kDa. Arrowheads indicate the HLTF proteins.Molecular Cancer 2006, 5:23 http://www.molecular-cancer.com/content/5/1/23
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Morphological observations
In a previous study, some of us have shown that the S100
protein was an early and specific marker of cell transfor-
mation related to DES tumorigenicity in the kidney,
appearing as soon as 4 months after beginning of drug
exposure [25]. Thus, kidneys of animals sacrificed at dif-
ferent time points during DES treatment were processed
for S100 as well as HLTF immunostaining. No morpho-
logical evidence of HLTF expression was noted in the renal
cortex of control animals, but a few collecting tubules
were found HLTF positive in the inner medulla of some
individuals. This point was not pursued further. Kidneys
of hamsters treated with DES for one month still appeared
negative for both HLTF and S100. A first evidence of
immunoreactive HLTF associated with early signs of neo-
plastic transformation was seen in the renal tissue of an
animal sacrificed two months after beginning of exposure
(Figure 3A). Kidneys of this individual and of the other
animals of the same group were still S100 negative. HLTF
positive cells were a consistent finding in medium size
and large tumors of animals treated with DES for 6
months or more. HLTF expression either occurred in scat-
tered cells (Figure 3B–C,), or was seen in tumor cell
groups (Figure 3D). Of note, with regard to immunostain-
ing intensity and distribution, no difference was observed
between the ASE2 and ART2 antisera. As specified above,
the appearance of S100 immunoreactivity was posterior
to that of HLTF since S100 positive cells were only seen
Alignment of the hamster and human HLTF cDNA sequences Figure 2
Alignment of the hamster and human HLTF cDNA sequences. A rapid amplification of cDNA 5' end (5' RACE) was performed 
on polyA(+) RNA extracted from hamster skeletal muscle: the product was cloned and its sequence is given in the top line. 
The segment in bold corresponds to the adaptor used in the 5' RACE. The human cDNA sequence is a fragment of GenBank 
#Z46606, with the same numbering (657 to 915). The cDNA sequences are identical over the entire length except for the 22-
bp segment boxed in red. The region encoding the HLTFMet123-specific peptide is highlighted in grey.Molecular Cancer 2006, 5:23 http://www.molecular-cancer.com/content/5/1/23
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Immunoperoxidase staining of HLTF in kidney and tumor tissue Figure 3
Immunoperoxidase staining of HLTF in kidney and tumor tissue. A-D, kidneys from DES-treated hamsters; E-F, HKT-1097-
derived tumor xenograft. Tissue sections were processed for HLTF immunostaining with antisera directed against either 
HLTFMet123 (ASE2; A, B, D) or HLTFMet1 (ART2; C, E, F). A, HLTF immunolabeling associated with early signs of neoplastic 
transformation (tumorous bud; two months of DES exposure). B, C, scattered HLTF-positive cells in large renal tumors (6 
months of DES exposure). D, cell populations with HLTF immunoreactivity in a large tumor (11 months of DES exposure). E, 
F, scattered HLTF-positive cells in subcutaneous tumor xenograft.Molecular Cancer 2006, 5:23 http://www.molecular-cancer.com/content/5/1/23
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after four months of DES exposure (not shown). Later on,
S100 and HLTF immunoreactivities were not systemati-
cally associated. Tumor cell populations could be HLTF
positive and S100 negative (Figure 4A–B,), HLTF negative
and S100 positive (Figure 4C–D,) or could exhibit both
markers (Figure 4E–F,). In the latter case, however, we did
Combined immunolocalization of HLTF (A, C, E) and S100 protein (B, D, F) in DES-induced renal tumors Figure 4
Combined immunolocalization of HLTF (A, C, E) and S100 protein (B, D, F) in DES-induced renal tumors. Immunostaining was 
performed with the ASE2 antiserum directed against HLTFMet123. A-B, C-D, E-F are corresponding fields in consecutive tis-
sue sections. A-B, a cluster of neoplastic cells with HLTF immunoreactivity (A) appears S100 negative (B) (7 months of DES 
exposure). C-D, a small tumor negative for HLTF (C) exhibits S100 immunoreactivity (D) (7 months of DES exposure). E-F, 
mixed population of HLTF-positive (E) and S100-positive (F) cells in a medium size tumor (6 months of DES exposure).Molecular Cancer 2006, 5:23 http://www.molecular-cancer.com/content/5/1/23
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not find clear-cut evidence of colocalization (i.e. HLTF
and S100 immunoreactivities occurred in distinct cells).
As shown previously, the HKT-1097 cell line derived from
DES-induced renal tumors shares a variety of markers
with the neoplasms of origin [29,30]. Immunofluores-
cence staining clearly demonstrated HLTF expression in
HKT-1097 cells (Figure 5). Simultaneous detection of
vimentin (an intermediate filament constitutively
expressed by HKT-1097 cells) and HLTF by double label
immunofluorescence revealed an equivalent level of HLTF
expression (as inferred from signal intensity) in all cells
(Figure 5A–B, E–F). Besides, combined detection of lamin
B (an intermediate filament associated with the nuclear
envelope) and HLTF unequivocally localized the latter
protein in cell nuclei (Figure. 5c–d, g–h). Similar immun-
ofluorescence patterns were found with the ASE2 (Figure
5B, D) and ART2 antisera (Figure 5G, F), although the sig-
nal periphery appeared less sharp with the latter, suggest-
ing a more heterogeneous distribution of the HLTFMet1
protein.
The tumorigenic potential of the HKT-1097 cell line has
been demonstrated by its ability to give rise to tumor
xenografts in nude mice. As illustrated in Figure 3(E,F),
HLTF immunostaining in HKT-1097-derived neoplasm
revealed the presence of scattered positive cells through-
out the tumor tissue. This suggests that HLTF expression
persists for many generations in subpopulations of tumor
cells.
Discussion
Genetic studies in human and mouse have shown that
inactivating mutations or deletions of genes encoding
subunits of the SWI/SNF complex were associated with
cancer, pointing these genes as putative tumor suppres-
sors. In keeping with this idea, inhibition of HLTF gene
expression caused by promoter hypermethylation was
recently observed in 30–70% of human colon cancers and
human gastric carcinoma [19,20]. The data that we are
presenting here on an animal model of kidney carcino-
genesis are in sharp contrast with previously published
observations. In fact, in the very study where HLTF was
initially found to be inactivated in a number of colon and
gastric cancers, neither HLTF promoter hypermethylation
nor loss of expression was found in cancers of other
organs such as the breast and the lung [20]. Moreover a
20-fold increase in HLTF mRNA was observed in trans-
formed cell lines derived from various tissues such as
breast, ovary, cervix...[11]. We confirmed ourselves these
data at the protein level since we showed by Western blot
high levels of HLTFMet1 and HLTFMet123 in HeLa (cervix
adenocarcinoma) and TE671 (rhabdomyosarcoma) cells
(data not shown).
Intriguingly, HLTF over-expression was never detected in
differential gene expression profiles performed between
tumor tissue and its normal counterpart. An explanation
might be found in the HLTF expression pattern that we
observed here during kidney tumor progression: although
every single cell stained for HLTF in tumor buds, the HLTF
signal was only detected in about 10% of cells scattered in
larger tumors. If a similar pattern occurred in tumors
derived from other tissues, the 10–20 fold increase in
HLTF expression in 10% of tumor cells would be diluted
out in the population of HLTF negative cells, and it might
not be detected upon analyses of whole tumor homoge-
nates. This hypothesis will have to be evaluated by analy-
ses of HLTF expression in clinical samples of early primary
tumours.
Preliminary observations have also shown on a model of
rat kidney regeneration that HLTF was expressed very tran-
siently (12–24 h) during the late steps of tubular cell dif-
ferentiation. (unpublished data). This restricted period of
expression associated with an asynchronous development
of tumoral foci might explain why only 10% of tumor
cells exhibit HLTF overexpression. An alternative explana-
tion is suggested by a recent work [35] indicating that a
small population of cells endowed with unique self-
renewal properties and tumorigenic potential is present in
tumors. According to this model, if HLTF is only expressed
by these cancer stem cells and their direct progeny, posi-
tive cells should appear randomly distributed within kid-
ney tumors.
In the present study, we have detected HLTF protein
expression at early stages of development of renal tumors
induced by DES in Syrian golden hamsters. The protein
was detected before the appearance of S100, an early
tumor marker previously identified in this model [25] :
indeed two months after initiating DES administration,
we already found tumor buds consisting of only a few
dozen cells that all exhibited strong immunostaining with
the antisera against HLTF. These observations also suggest
that HLTF is a precocious marker expressed either simul-
taneously with or even before other known markers of
estrogen-induced kidney tumours such as ER, PR [36], c-
MYC, c-FOS [37] or cyclins E, D1 [38].
Some of us have recently used an anti-galectin-1 antibody
for immunohistochemical staining in the same cancer
model, and detected small clusters of presumably preneo-
plastic cells at the corticomedullary junction already one
week after starting DES administration. After one month
of exposure, tumorous buds positive for both galectin-1
and 3 were detected at the same location, in the perivascu-
lar connective tissue next to large blood vessels [39]. These
data suggested that these galectins might be involved in
the early carcinogenesis stages of this model. Intriguingly,Molecular Cancer 2006, 5:23 http://www.molecular-cancer.com/content/5/1/23
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Immunofluorescence staining of HLTF in renal tumor-derived HKT-1097 cells Figure 5
Immunofluorescence staining of HLTF in renal tumor-derived HKT-1097 cells. Cultured cells were processed for double 
immunofluorescence staining as described in Materials and methods. A, E: general cell appearance revealed by vimentin immu-
nostaining (FITC immunolabeling); B, F: virtually all cells in the microscopic fields display HLTF immunoreactivity as shown by 
application of antisera (Texas Red labeling) directed against either HLTFMet123 (ASE2; B) or HLTFMet1 (ART2; F). C, G: cell 
nuclei immunolabeled with anti-lamin B serum (Texas Red labeling); D, H: use of ASE2 (D) or ART2 (H) (FITC labeling) reveals 
the nuclear localization of immunoreactive HLTF variants.Molecular Cancer 2006, 5:23 http://www.molecular-cancer.com/content/5/1/23
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such an implication was also suggested in human colon
cancer [40] where HLTF is inactivated by hypermethyla-
tion of its promoter. HLTF (this study) as well as galectin-
1 and 3 [39] are expressed in every cell of the established
HKT-1097 line grown in vitro, raising the possibility that
HLTF might activate galectin-1 and -3 gene expression. It
will thus be very interesting to evaluate whether the same
cells might express these proteins in the hamster kidney
cancer model by co-immunostaining with galectin-1 and
3 at various stages of tumor development, including very
early stages of DES treatment when only galectin-1 is
detected.
Finally, converging information suggest that the estrogen-
induced tumors could arise from germinal interstitial
stem cells [24,36] or from an unidentified precursor cell
associated to the sheath of Schwann cells [25]. These
observations thus suggest that HLTF could be a marker of
undifferentiated cells and not directly related to the mech-
anisms of carcinogenesis. Yet, previous observations of
HLTF expression in mice embryos [11] and in a model of
rat kidney regeneration (unpublished data) have shown
that HLTF is detected very late in the course of tissue dif-
ferentiation.
We observed a rarefaction and a scattered distribution of
HLTF positive cells during tumor progression. Several rea-
sons could be put forward to explain those data. First, the
few cells that form the tumoral bud might evolve to form
different clonal populations showing different pheno-
typic drifts. Indeed, some of us have shown that progres-
sion of DES-induced renal tumor from tumor buds to
advanced malignancies was associated with phenotypic
variation and clonal divergence of neoplastic cells [41].
Another hypothesis is that HLTF over-expression might be
involved in early steps of cellular transformation, and
could later on be replaced by a more efficient survival
strategy consisting of genetic alterations that would confer
higher proliferative/invasive capacity. Indeed, HLTF
expression did not seem linked to proliferation since
HLTF-positive cells and proliferating cells (BrdU staining,
not shown) belonged to distinct subpopulations. Moreo-
ver, if all cells were HLTF positive in HKT-1097 cells cul-
tured  in  vitro, the same decrease in HLTF signal was
observed in tumours derived from these cells in nude
mice (Fig 3E–F,). Other studies have indicated that HLTF
expression was coupled to terminal differentiation in
mouse development [11]: one could imagine that even if
HLTF over-expression were to favor immortalization, it
might still slow down proliferation. In this line of reason-
ing, during tumor progression, tumor cells might circum-
vent the antiproliferative effect of HLTF  gene by
hypermethylation, as observed in advanced colon adeno-
mas [20]. The observation that some HLTF-positive cells
always remain present during progression and are found
scattered in the tumor mass is suggestive of a paracrine
interaction: HLTF-positive cells might stimulate prolifera-
tion of the surrounding HLTF-negative cells by secretion
of different growth factors.
There is also ample information showing that estrogen-
induced aneuploidy is detected in both early tumor foci
and in primary tumors of the kidney [36]. This chromo-
somal instability seems to be elicited in kidney multipo-
tent interterstitial stem cells by an overexpression of c-myc,
subsequent to estrogen administration [42]. Currently,
the involvement of HLTF in this estrogen-induced mecha-
nism has not been fully explored but preliminary observa-
tions suggest that HLTF could play a role in generation of
aneuploidy. Indeed, we have detected, by using a yeast
two-hybrid screen with an HLTF domain as the bait
(unpublished observations), a cDNA encoding the kine-
tochore protein (CENPE) [43]. This suggests a potential
involvement of HLTF in the movement of mammalian
chromosomes and in spindle elongation.
One of the rationale behind the present study was that the
HLTF gene encoded two protein variants with different
biological functions, only the shorter of which
(HLTFMet123) presented a transcriptional activity [1,13].
In the present study, we wondered whether an imbalance
in the variant ratio might be linked to transformation.
However no difference could be found in the immunos-
taining patterns demonstrated by the specific antisera
(ART2 and ASE2) raised against the individual variants. A
word of caution should be given here to rule out a puta-
tive artifact. The immunogenic peptide "specific" for
HLTFMet123 is also present in HLTFMet1, and the specif-
icity of the ASE2 serum only relies on the three-dimen-
sional structure of the larger amino-terminal domain in
HLTFMet1 where the sequence of the peptide used to raise
ASE2 is buried. One could argue that the microwave pre-
treatment of renal sections performed for antigen retrieval
could have denatured the HLTF proteins and expose this
immunogenic peptide, allowing recognition of the
HLTFMet1 protein by the antiserum "specific" of
HLTFMet123. However, the immunofluorescence stain-
ing of HKT-1097 cells did not involve such harsh treat-
ment and anyway revealed very similar staining patterns
for both antisera, with just a fuzzier HLTFMet1 staining at
the nuclear periphery as compared to HLTFMet123 (Fig-
ure 5B, Dvs Figure 5F, H). Interestingly the HLTF RING
domain has been found to interact with an atypical Type
IV P-type ATPase, a putative phospholipid pump located
at the inner nuclear membrane [44].
The HLTF proteins were previously shown to locate in the
nucleoplasm of HeLa cells, as expected for SWI/SNF pro-
teins [1]. In the present study, a nuclear localization was
also clearly observed in HKT-1097 cells fixed in parafor-Molecular Cancer 2006, 5:23 http://www.molecular-cancer.com/content/5/1/23
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maldehyde. In contrast, in the kidney tumors fixed in
alcoholic Bouin's mixture, most HLTF-positive cells pre-
sented a strong cytoplasmic signal, while only few cells
displayed a nuclear staining. Again, the different locations
observed between cells in culture and tumoral tissues
might be artefactual and caused by tissue processing (fix-
ation, dehydratation, dewaxing) and/or the treatment
applied for antigen retrieval. Alcoholic Bouin's mixture
was not used for HKT-1097 cells, but experiments using
another alcoholic fixation method (Carnoy) on these cells
indeed showed a significant alteration of the nuclear sig-
nal (data not shown). However, in a few tumor samples
that were fixed in paraformaldehyde we could detect the
same proportion of HLTF-positive cells with strong
cytosolic staining as found in the present study (data not
shown), suggesting other explanations than processing
artefacts. A similar conclusion was drawn in a previous
study on the p53 oncoprotein [45]. It showed that the
cytoplasmic distribution of TP53 was genuine and not the
result of pre-treatments like poor fixation or antigen
unmasking, and that the latter actually improved the qual-
ity of the immunocytochemical reaction [45]. Several
examples are known of transcription factors or associated
cofactors that shuttle between the nucleus and the cyto-
plasm according to various stimuli. Sequestration in a cel-
lular compartment is indeed a way to regulate
transcription activity. NFκB is a classical example: it is
kept inactive as a cytoplasmic complex with IκB until the
latter undergoes phosphorylation and proteosomal degra-
dation, releasing NFκB that migrates to the nucleus for
transcription activation (reviewed by [46]). Conversely,
MEF2 is sequestered in an inactive nuclear complex with
a histone deacetylase that is translocated to the cytoplasm
upon phosphorylation by a calcium-dependent kinase,
allowing MEF2 to activate transcription of genes involved
in terminal muscle differentiation [47]. One could
hypothesize that sequestration of HLTF outside of the
nucleus might be part of the transformed phenotype as
shown previously for p27Kip, a negative regulator of the
cell cycle that accumulates in the cytoplasm of colorectal
tumors [48].
Conclusion
In conclusion, our data suggest that HLTF protein expres-
sion is linked to early transformation in a model of hor-
monal carcinogenesis and that HLTF protein detection
might be of value as an early marker in some human can-
cers.
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